Egis Pharmaceuticals PLC

egis.hu

Egis Pharmaceuticals PLC, headquartered in Budapest, Hungary, is one of the leading pharmaceutical companies operating principally in Central and Eastern Europe, Russia and the CIS region. Our history dates back to more than a century and our activities extend to every field of the pharmaceutical value chain: from R&D through the production of APIs and FPs to sales and marketing. Our products ranging from tablets to injections and galenic products are sold in almost 60 countries worldwide. Besides Hungary we sell our products under the brand name Egis in 17 countries through our network of subsidiaries and representative offices.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

OPTUM DRIVES UNITEDHEALTH’S BETTER-THAN-EXPECTED EARNINGS

MedCity News - | January 16, 2020

news image

In a year when healthcare costs continued to increase, UnitedHealth Group reported better-than-expected results at the end of 2019. The company reported earnings of $19.68 billion in 2019, up 13 percent year-over-year. UnitedHealth saw improving margins in most of its business segments, with its Optum segment reporting double-digit growth across the board. The company also managed to grow its already large presence in the Medicare Advantage market, despite several new competitors. Overall, Unite...

Read More

HUATENG PHARMA DEVELOPS SPRAY AGAINST NEW CORONAVIRUS INFECTION

Huateng Pharma | February 11, 2020

news image

This year is an unusual year due to the infection of the Novel Coronavirus Pneumonia (NCP) epidemic. Hunan Huateng Pharmaceutical Co., Ltd. (hereinafter referred to as Huateng), as a drug research and development company with rich experience in developing antiviral drugs, has attached close attention to this matter. Considering that there is no targeted medicine for novel coronavirus pneumonia (NCP) infection and that NCP virus is highly similar to SARS / Middle East Respiratory Syndrome (MERS) ...

Read More

BUSINESS INSIGHTS, PHARMA TECH

NEOCHROMOSOME ANNOUNCES SUCCESSFUL COLLABORATION WITH SUMITOVANT BIOPHARMA

Sumitovant Biopharma, Inc. | January 20, 2023

news image

On January 19, 2023, Neochromosome, Inc., announced a partnership with Sumitovant Biopharma, Inc., a technology-driven biopharmaceutical firm expediting the discovery and commercialization of novel therapeutics. This collaboration blends Neochromosome's neoYeast™ platform with Sumitovant's DrugOME™ computational ecosystem to identify new proteins that would benefit from non-canonical amino acid chemistries that are unavailable in nature. As part of...

Read More

BUSINESS INSIGHTS

CYCLENIUM PHARMA AND VUJA DE SCIENCES ANNOUNCE ONCOLOGY DRUG DISCOVERY COLLABORATION

Cyclenium Pharma | January 06, 2022

news image

Cyclenium Pharma, Inc. an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, and Vuja De Sciences, Inc. a biotechnology startup dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence, have announced today the signing of a drug discovery collaboration agreement. The companies will ...

Read More
news image

OPTUM DRIVES UNITEDHEALTH’S BETTER-THAN-EXPECTED EARNINGS

MedCity News - | January 16, 2020

In a year when healthcare costs continued to increase, UnitedHealth Group reported better-than-expected results at the end of 2019. The company reported earnings of $19.68 billion in 2019, up 13 percent year-over-year. UnitedHealth saw improving margins in most of its business segments, with its Optum segment reporting double-digit growth across the board. The company also managed to grow its already large presence in the Medicare Advantage market, despite several new competitors. Overall, Unite...

Read More
news image

HUATENG PHARMA DEVELOPS SPRAY AGAINST NEW CORONAVIRUS INFECTION

Huateng Pharma | February 11, 2020

This year is an unusual year due to the infection of the Novel Coronavirus Pneumonia (NCP) epidemic. Hunan Huateng Pharmaceutical Co., Ltd. (hereinafter referred to as Huateng), as a drug research and development company with rich experience in developing antiviral drugs, has attached close attention to this matter. Considering that there is no targeted medicine for novel coronavirus pneumonia (NCP) infection and that NCP virus is highly similar to SARS / Middle East Respiratory Syndrome (MERS) ...

Read More
news image

BUSINESS INSIGHTS, PHARMA TECH

NEOCHROMOSOME ANNOUNCES SUCCESSFUL COLLABORATION WITH SUMITOVANT BIOPHARMA

Sumitovant Biopharma, Inc. | January 20, 2023

On January 19, 2023, Neochromosome, Inc., announced a partnership with Sumitovant Biopharma, Inc., a technology-driven biopharmaceutical firm expediting the discovery and commercialization of novel therapeutics. This collaboration blends Neochromosome's neoYeast™ platform with Sumitovant's DrugOME™ computational ecosystem to identify new proteins that would benefit from non-canonical amino acid chemistries that are unavailable in nature. As part of...

Read More
news image

BUSINESS INSIGHTS

CYCLENIUM PHARMA AND VUJA DE SCIENCES ANNOUNCE ONCOLOGY DRUG DISCOVERY COLLABORATION

Cyclenium Pharma | January 06, 2022

Cyclenium Pharma, Inc. an emerging pharmaceutical company specializing in the discovery and development of novel therapeutic agents based on their proprietary macrocyclic chemistry, and Vuja De Sciences, Inc. a biotechnology startup dedicated to discovering therapies that target the unique vulnerability of undetected disseminated tumor cells before they can cause deadly metastatic cancer recurrence, have announced today the signing of a drug discovery collaboration agreement. The companies will ...

Read More